Crescita Therpeutc (TSE:CTX) has released an update.
Crescita Therapeutics Inc. reports a decrease in Q2 2024 revenue and gross profit but maintains a strong balance sheet, allowing for strategic investments. Despite these challenges, the company has secured a US$10 million manufacturing contract and completed a significant asset acquisition, setting the stage for potential long-term profitability.
For further insights into TSE:CTX stock, check out TipRanks’ Stock Analysis page.
